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Stem cell policy needs to keep pace with the torrid progress of
stem cell science. Since the November 2007 announcement
that induced pluripotential cells could be derived from human
somatic cells, many scientists have shifted their focus from at-
tempting human somatic cell nuclear transfer (SCNT) to deriving
pluripotential cells whose nuclear DNAmatches that of a specific
donor. Correspondingly, many contentious policy debates may
now be moot, including debates over payment for fresh oocytes
donated specifically for research, the safety of hormonal manip-
ulation and oocyte retrieval, the use of SCNT as a research tool,
and the creation of human-animal cytoplasmic hybrids. Although
additional embryonic stem cell lines are still needed, it is likely
that they will be derived from frozen embryos remaining after
a woman or couple has competed infertility treatment. Research
use of frozen embryos still evokes controversy, but less intensely
than creating embryos specifically for research.
The Stem Cell Century, by UCLA law professor Russell Korob-
kin, is a clear, well-reasoned analysis of important issues in stem
cell policy. Over one-half of the book primarily concerns embry-
onic stem cell research and SCNT, and therefore, in the eyes of
this reviewer, is now of primarily historical interest. In addition,
the book’s analysis of payment for materials used in research
is less salient with regard to research with somatic cells and fro-
zen embryos. The additional procedures required to obtain these
materials are far less invasive or risky than oocyte retrieval, and
payment to donors beyond expenses is either not offered or at
a de minimus level.
A number of chapters address ongoing public policy issues,
such as patents, profits from publicly funded research, and com-
pensation to donors. While enlightening, these chapters focus
narrowly on legal scholarship, particularly on close analysis of
court rulings and the reasoning behind policy alternatives. How-
ever, in the real world, policies will also be driven by negotiation,
compromise, and timing, and many other factors need to be
considered.
Patent reform is heatedly debated, not just for biotechnology
but also for other new forms of knowledge. The broad scope of
Wisconsin Alumni Research Foundation (WARF) human embry-
onic stem cell patents has been challenged, and a preliminary
ruling invalidated three patents in April 2007. The author does
not discuss a number of reports addressing patent reform in bio-
technology, which raise issues and offer options beyond those
his book considers. The National Academy of Sciences issued
a consensus-based, peer-reviewed report entitled A Patent
System for the 21st Century (ed. S.A. Merrill, R.C. Levin, and
M.B. Myers [Washington, D.C.: National Academies Press,
2004]). This report recommended that inconsistencies amongUS, European, and Japanese patent systems be reduced. The
report also recommended reinvigorating the nonobviousness
standard by instituting an Open Review procedure in which third
parties can challenge patents before an administrative law
judge. These procedures would include expert testimony. As
regards the WARF patents, a key issue is whether other scien-
tists would have found the innovation to be obvious at that
time. Resolving this issue requires expert scientific testimony.
Certainly, a full policy analysis would consider a wider range of
issues and options, which traditional legal scholarship might
not identify.
The taxpayers’ stake in profits frompublicly funded research is
the topic of another chapter. Current NIH policy allows grantees
to patent discoveries and to retain royalty and licensing pay-
ments, with no return to the federal treasury even for blockbuster
patents. The author carries out a careful policy analysis of
sharing of licensing revenues, articulating the options and point-
ing out inconsistencies in various positions and arguments.
Although such analysis is helpful, public policy is shaped in the
political arena. The revenue-sharing policy of the California Insti-
tute for Regenerative Medicine (CIRM), which will award 3 billion
dollars in state funding for stem cell research, is an important
case study (see http://www.cirm.ca.gov/policy/policy.asp).Cell Stem Cell 2, March 2008 ª2008 Elsevier Inc. 203
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ment that depends on the amount of licensing revenue gener-
ated by a patent based on CIRM-funded research. A number
of issues had to be decided, including a distinction between
for-profit and not-for-profit grantees, policies for licensing of
patents and for profits from commercial products, a threshold
level that triggers higher payments in the case of blockbuster
patents, a cap on payments relative to the size of the original
CIRM grant, and access to treatments for patients who are unin-
sured or who receive care through public funding. Each of these
issues deserves further analysis. The author suggests that a pro-
posed return to the state of 25% of company-held licensing
revenues exceeding $500,000 is too low, and suggests that
50% is probably more appropriate, without explaining why this
is the case. Based on presentations at public meetings, how-
ever, a 50% level of sharing would likely lead for-profit compa-
nies to eschew CIRM funding, leading to possible delays at early
stages of the development of cellular-based therapies. In turn,
patient advocates would have rejected such a revenue-sharing
policy, fearing that it might delay the development of therapies.
Thus different interest groups, policy objectives, and incentives
needed to be balanced. Negotiations involved a variety of in-
terest groups, including research institutions, public interest
groups, disease advocacy groups, venture capitalists, and for-
profit biotechnology firms. The CIRM revenue-sharing policies
(which are still not yet final) resulted from 15 public meetings
and formal public comments on proposed policies. The process
involved give-and-take over the entire set of issues. Whether the
top level of revenue sharing should be 25%, 50%, or some other
percentage needs to be viewed in the context of the other issues.
A chapter on default rules for tissue donations takes as a start-
ing point the decision in the landmark Moore case, which raised
the issue of property rights with regard to human tissues. The au-
thor analyzes the nature of property rights and suggests default
rules that should apply when the researcher and tissue donor
have not made a clear agreement regarding compensation for
donated tissue. However, this analysis has little implication for
research using somatic cells or frozen embryos. Unlike oocyte
donation, there is little need for high compensation to attract
donors. Standard practice now is to include in the consent
form for donation explicit statements that the researcher may
patent discoveries using the tissue and that the donor will not
share in any financial benefits. Thus, the author’s proposed
solution has already been adopted and accepted. His careful
analysis yields no new policy recommendations.
The book’s analysis of compensation focuses on individual
donors. However, an important issue is potential benefit to
a class of patients with a specific disease, whose tissues are
of particular value to researchers. The case of Greenberg versus
Miami Children’s Hospital Research Institute is an illustrative204 Cell Stem Cell 2, March 2008 ª2008 Elsevier Inc.example. Parents of children with Canavan disease helped a re-
searcher obtain tissue and funding. Their understandingwas that
any diagnostic tests would be affordable and accessible. When
the researcher patented the genomic sequence for the Canavan
disease and charged licensing fees for a Canavan diagnostic test
that made the test unaffordable, the parents sued. The plaintiffs
lost in the appellate courts, but an out-of-court settlement was
reached and sealed. The author analyzes the legal reasoning
behind the appellate ruling and points out its logical inconsis-
tency. However, the author does not follow up on the concerns
of disease advocacy groups for affordable and accessible tests
and treatment resulting from donated tissues, particularly when
their cooperation in obtaining such tissue greatly facilitates the
research. These issues will likely be settled through negotiations
between advocacy groups and researchers; advocacy groups
are becoming savvier at making these arrangements explicit at
the beginning of a research project. It is likely that other disease
advocacy groups will also become better negotiators and
narrow the balance of power between researchers and patient
groups.
A number of important policy issues will likely emerge regard-
ing stem cell science. Clinical trials of stem cell interventions
have been carried out using cord blood stem cells and autolo-
gous adult stem cells. The safety of these interventions has
been well established. However, interventions using cells de-
rived from embryonic stem cells and fetal tissue are carried out
in multiple countries where there are few to no requirements
for oversight or for evaluation of clinical outcomes and safety.
The International Society for Stem Cell Research (ISSCR) has
convened a task force working on guidelines for stem cell clinical
trials. One issue is whether stem cell scientists as a professional
group should affirm their commitment to valid and generalizable
knowledge and to well-designed clinical trials of innovative stem
cell interventions. Another issue is how to help potential partici-
pants make informed decisions about participating in these
clinical trials, while allowing them to maintain hope. Other stake-
holders in clinical trials, particularly regulatory agencies, scien-
tific review bodies, and institutional review boards, should start
to develop policies and regulations for such clinical trials. In-
sightful scholars such as Prof. Korobkin could contribute to the
development of such policies. One challenge will be for them
to disseminate their work in a way that has greater impact on
real-time policy development. Publishing books or articles in
law and policy journals may not, in a timely manner, reach scien-
tists who are helping to develop public and institutional policies.
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